David S Chang, MD
Internal Medicine · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chang’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence C149397 · Current
Licensed to practise in California · since 2017 · expires 2028-09-30 · Tufts University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$12,412
Medicare paid this office $12,412 for 156 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 72 | $4,206 | $47 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 55 | $3,890 | $71 |
| Short return visit (20+ min) | 29 | $2,368 | $61 |
| Return visit (30+ min) | 15 | $1,104 | $58 |
Who their Medicare patients are
156 Original Medicare patients in 2024. Average age 73 · Under 65 11% · 85 and older 9% · Women 49% · Also on Medicaid 31% · Health risk score 1.18. At or below the middle of the specialty; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 62% · Diabetes 28% · Chronic kidney disease 21% · Coronary heart disease 20% · Atrial fibrillation 17% · Heart failure 14% · Cancer 14% · Depression 13% · Stroke 9%.
The office billed $80,441, Medicare allowed $17,415 and paid $12,412; for 227 services of 9 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 156 | 227 | 73 | 1.18 | $80,441 | $12,412 |
| 2023 | 177 | 277 | 73 | 1.33 | $103,245 | $15,716 |
| 2022 | 142 | 223 | 71 | 1.23 | $96,493 | $14,678 |
| 2021 | 126 | 208 | 71 | 1.52 | $89,649 | $13,483 |
| 2020 | 188 | 290 | 71 | 1.34 | $102,822 | $21,199 |
| 2019 | 96 | 126 | 71 | 1.19 | $23,931 | $10,577 |
| 2015 | 27 | 27 | 77 | 3.50 | $4,145 | $1,902 |
| 2014 | 24 | 26 | 76 | 3.11 | $3,331 | $1,529 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 3 services
| Short return visit (20+ min) | 92 | $5,975 | $51 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 63 | $4,449 | $71 |
| Return visit (30+ min) | 59 | $4,381 | $53 |
2022: 3 services
| Return visit (30+ min) | 74 | $7,340 | $62 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 44 | $3,359 | $76 |
| Short return visit (20+ min) | 34 | $2,035 | $52 |
2021: 2 services
| Return visit (30+ min) | 85 | $8,669 | $61 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 41 | $2,930 | $71 |
2020: 5 services
| Return visit (30+ min) | 120 | $10,700 | $66 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 16 | $2,242 | $140 |
| Return visit (30+ min) | 21 | $1,394 | $66 |
| Telephone medical discussion with physician, 21-30 minutes | 11 | $1,018 | $73 |
| Telephone medical discussion with physician, 11-20 minutes | 20 | $800 | $38 |
2019: 2 services
| Return visit (30+ min) | 75 | $6,803 | $72 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 12 | $1,700 | $142 |
2014: 1 service
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $1,174 | $56 |
Medicaid work
$45,700 in 2024
Medicaid paid $45,700 for 740 billed services this clinician did in 2024, up to 42 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 412 | $44,912 |
| Short return visit (20+ min) | 263 | $537 |
| Return visit (30+ min) | 47 | $142 |
| Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 18 | $109 |
| 2024 | 740 | 4 | 42 | $45,700 |
| 2023 | 176 | 3 | 29 | $10,397 |
| 2022 | 14 | 1 | 14 | $34 |
| 2021 | 31 | 1 | 19 | $355 |
| 2020 | 54 | 1 | 14 | $1,495 |
| 2019 | 25 | 1 | 12 | $183 |
See the largest Medicaid services in earlier years
2023
| Clinic visit/encounter, all-inclusive | 91 | $9,635 |
| Short return visit (20+ min) | 38 | $386 |
| Return visit (30+ min) | 47 | $376 |
2022
| Return visit (30+ min) | 14 | $34 |
2021
| Return visit (30+ min) | 31 | $355 |
2020
| Return visit (30+ min) | 54 | $1,495 |
2019
| Return visit (30+ min) | 25 | $183 |
Drugs they prescribed that Part D paid
$134,173
Pharmacies billed $134,173 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 4% of their Part D prescriptions (41 of 1,171) in 2024. Above the middle of the specialty; the typical internal medicine clinician is at 1%.
1,022 generic and fewer than 11 brand-name prescriptions · $134,173 in drug cost · 18 antibiotic prescriptions to 12 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Jardiance | 30 | $37,111 | $1,237 |
| Mounjaro | 14 | $16,937 | $1,210 |
| Eliquis | 12 | $13,270 | $1,106 |
| Atorvastatin | 148 | $1,406 | $10 |
| Albuterol Sulfate Hfa | 20 | $1,300 | $65 |
See all 24 drugs
| Jardiance | 30 | $37,111 | $1,237 |
| Mounjaro | 14 | $16,937 | $1,210 |
| Eliquis | 12 | $13,270 | $1,106 |
| Atorvastatin | 148 | $1,406 | $10 |
| Albuterol Sulfate Hfa | 20 | $1,300 | $65 |
| Butalbital-Acetaminophen-Caffe | 12 | $846 | $71 |
| Hydrocodone-Acetaminophen | 17 | $681 | $40 |
| Levothyroxine | 52 | $630 | $12 |
| Rosuvastatin | 18 | $571 | $32 |
| Oxycodone | 19 | $524 | $28 |
| Duloxetine | 14 | $517 | $37 |
| Baclofen | 11 | $482 | $44 |
| Amlodipine Besylate | 56 | $439 | $8 |
| Metformin | 51 | $363 | $7 |
| Tamsulosin | 12 | $346 | $29 |
| Losartan | 40 | $302 | $8 |
| Trazodone | 22 | $260 | $12 |
| Lisinopril | 64 | $225 | $4 |
| Hydrochlorothiazide | 38 | $137 | $4 |
| Gabapentin | 17 | $136 | $8 |
| Sertraline | 17 | $62 | $4 |
| Diazepam | 12 | $53 | $4 |
| Metformin Hcl Er | 11 | $44 | $4 |
| Simvastatin | 12 | $18 | $2 |
Year by year
| 2024 | 1,171 | 178 | 4% (41) | None | $134,173 |
| 2023 | 1,357 | 182 | 3% (40) | None | $185,239 |
| 2022 | 1,388 | 228 | 4% (49) | None | $145,857 |
| 2021 | 1,612 | 269 | 5% (79) | None | $158,156 |
| 2020 | 1,636 | 242 | 5% (86) | None | $176,062 |
| 2019 | 378 | 121 | 10% (39) | 13% | $29,620 |
| 2018 | 16 | None | 0% (0) | None | $2,109 |
| 2017 | 12 | None | 0% (0) | None | $867 |
| 2015 | 16 | None | None | None | $216 |
| 2013 | 25 | None | None | None | $859 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 32 drugs
| Eliquis | 26 | $31,944 | $1,229 |
| Jardiance | 21 | $28,561 | $1,360 |
| Colchicine | 15 | $3,055 | $204 |
| Atorvastatin | 141 | $1,975 | $14 |
| Butalbital-Acetaminophen-Caffe | 15 | $1,715 | $114 |
| Fluoxetine | 13 | $1,653 | $127 |
| Amlodipine Besylate | 82 | $1,180 | $14 |
| Losartan | 58 | $962 | $17 |
| Levothyroxine | 49 | $905 | $18 |
| Metformin | 71 | $877 | $12 |
| Lisinopril | 72 | $844 | $12 |
| Hydrocodone-Acetaminophen | 16 | $775 | $48 |
| Rosuvastatin | 13 | $614 | $47 |
| Terazosin | 15 | $565 | $38 |
| Albuterol Sulfate Hfa | 18 | $528 | $29 |
| Trazodone | 32 | $465 | $15 |
| Omeprazole | 15 | $343 | $23 |
| Duloxetine | 15 | $338 | $23 |
| Gabapentin | 20 | $337 | $17 |
| Carvedilol | 11 | $317 | $29 |
| Oxycodone | 18 | $313 | $17 |
| Hydrochlorothiazide | 34 | $248 | $7 |
| Tamsulosin | 15 | $221 | $15 |
| Simvastatin | 14 | $219 | $16 |
| Metoprolol | 14 | $198 | $14 |
| Sertraline | 13 | $194 | $15 |
| Clopidogrel | 11 | $192 | $17 |
| Metformin Hcl Er | 16 | $181 | $11 |
| Cyclobenzaprine | 11 | $146 | $13 |
| Diazepam | 15 | $120 | $8 |
| Alendronate | 14 | $119 | $8 |
| Nitroglycerin | 21 | $85 | $4 |
2022: 36 drugs
| Trulicity | 12 | $25,569 | $2,131 |
| Jardiance | 13 | $14,076 | $1,083 |
| Xarelto | 12 | $10,287 | $857 |
| Atorvastatin | 134 | $2,099 | $16 |
| Butalbital-Acetaminophen-Caffe | 13 | $1,486 | $114 |
| Levothyroxine | 66 | $1,309 | $20 |
| Tamsulosin | 22 | $1,098 | $50 |
| Synthroid | 12 | $1,042 | $87 |
| Albuterol Sulfate Hfa | 21 | $1,031 | $49 |
| Gabapentin | 33 | $960 | $29 |
| Hydrocodone-Acetaminophen | 18 | $785 | $44 |
| Amlodipine Besylate | 74 | $750 | $10 |
| Rosuvastatin | 12 | $658 | $55 |
| Losartan | 53 | $629 | $12 |
| Lisinopril | 58 | $622 | $11 |
| Terazosin | 11 | $473 | $43 |
| Metformin | 44 | $423 | $10 |
| Trazodone | 19 | $334 | $18 |
| Clonazepam | 12 | $329 | $27 |
| Simvastatin | 24 | $329 | $14 |
| Carvedilol | 15 | $323 | $22 |
| Pantoprazole | 14 | $286 | $20 |
| Clopidogrel | 18 | $286 | $16 |
| Famotidine | 11 | $257 | $23 |
| Oxycodone | 19 | $250 | $13 |
| Metoprolol | 11 | $237 | $22 |
| Zolpidem | 19 | $217 | $11 |
| Alendronate | 16 | $208 | $13 |
| Cyclobenzaprine | 12 | $197 | $16 |
| Triamterene-Hydrochlorothiazid | 11 | $180 | $16 |
| Hydrochlorothiazide | 38 | $173 | $5 |
| Omeprazole | 17 | $172 | $10 |
| Atenolol | 13 | $149 | $11 |
| Diazepam | 12 | $98 | $8 |
| Ibuprofen | 12 | $97 | $8 |
| Glipizide | 15 | $56 | $4 |
2021: 37 drugs
| Trulicity | 22 | $29,099 | $1,323 |
| Atorvastatin | 132 | $2,554 | $19 |
| Synthroid | 18 | $1,749 | $97 |
| Levothyroxine | 64 | $1,284 | $20 |
| Albuterol Sulfate Hfa | 19 | $919 | $48 |
| Ventolin Hfa | 14 | $831 | $59 |
| Hydrocodone-Acetaminophen | 34 | $805 | $24 |
| Losartan | 59 | $700 | $12 |
| Amlodipine Besylate | 80 | $664 | $8 |
| Bupropion Xl | 15 | $639 | $43 |
| Lisinopril | 50 | $606 | $12 |
| Clonazepam | 31 | $565 | $18 |
| Metoprolol | 26 | $558 | $21 |
| Duloxetine | 15 | $477 | $32 |
| Clopidogrel | 20 | $435 | $22 |
| Trazodone | 23 | $426 | $19 |
| Gabapentin | 26 | $405 | $16 |
| Rosuvastatin | 12 | $385 | $32 |
| Omeprazole | 28 | $360 | $13 |
| Allopurinol | 14 | $354 | $25 |
| Hydrochlorothiazide | 58 | $350 | $6 |
| Triamterene-Hydrochlorothiazid | 16 | $333 | $21 |
| Terazosin | 12 | $325 | $27 |
| Alendronate | 21 | $319 | $15 |
| Pantoprazole | 13 | $306 | $24 |
| Simvastatin | 34 | $306 | $9 |
| Carvedilol | 11 | $246 | $22 |
| Spironolactone | 11 | $244 | $22 |
| Metformin | 34 | $240 | $7 |
| Oxycodone | 20 | $235 | $12 |
| Fluticasone Propionate | 12 | $201 | $17 |
| Lovastatin | 12 | $182 | $15 |
| Lorazepam | 19 | $176 | $9 |
| Montelukast | 18 | $163 | $9 |
| Furosemide | 12 | $150 | $12 |
| Zolpidem | 16 | $132 | $8 |
| Triamcinolone Acetonide | 17 | $56 | $3 |
2020: 43 drugs
| Xarelto | 11 | $7,620 | $693 |
| Atorvastatin | 131 | $2,223 | $17 |
| Levothyroxine | 47 | $1,319 | $28 |
| Synthroid | 13 | $1,279 | $98 |
| Bupropion Xl | 15 | $1,019 | $68 |
| Albuterol Sulfate Hfa | 23 | $969 | $42 |
| Losartan | 70 | $897 | $13 |
| Ventolin Hfa | 13 | $748 | $58 |
| Hydrocodone-Acetaminophen | 36 | $690 | $19 |
| Amlodipine Besylate | 89 | $653 | $7 |
| Clonazepam | 28 | $649 | $23 |
| Duloxetine | 14 | $619 | $44 |
| Gabapentin | 23 | $589 | $26 |
| Trazodone | 23 | $574 | $25 |
| Tamsulosin | 13 | $531 | $41 |
| Diclofenac | 18 | $513 | $29 |
| Rosuvastatin | 14 | $502 | $36 |
| Metformin | 52 | $478 | $9 |
| Metoprolol | 20 | $397 | $20 |
| Lovastatin | 13 | $356 | $27 |
| Omeprazole | 26 | $342 | $13 |
| Metformin Hcl Er | 22 | $326 | $15 |
| Lisinopril | 38 | $320 | $8 |
| Simvastatin | 35 | $316 | $9 |
| Spironolactone | 13 | $295 | $23 |
| Triamterene-Hydrochlorothiazid | 13 | $286 | $22 |
| Furosemide | 26 | $263 | $10 |
| Butalbital-Acetaminophen-Caffe | 11 | $255 | $23 |
| Clopidogrel | 15 | $246 | $16 |
| Alendronate | 19 | $242 | $13 |
| Hydralazine | 11 | $234 | $21 |
| Atenolol | 15 | $219 | $15 |
| Oxycodone | 19 | $216 | $11 |
| Hydrochlorothiazide | 50 | $211 | $4 |
| Carvedilol | 19 | $151 | $8 |
| Escitalopram | 11 | $130 | $12 |
| Montelukast | 20 | $128 | $6 |
| Zolpidem | 19 | $116 | $6 |
| Tizanidine | 15 | $93 | $6 |
| Glipizide | 12 | $93 | $8 |
| Diazepam | 14 | $78 | $6 |
| Meloxicam | 13 | $52 | $4 |
| Triamcinolone Acetonide | 13 | $46 | $4 |
2019: 3 drugs
| Hydrocodone-Acetaminophen | 15 | $551 | $37 |
| Atorvastatin | 20 | $346 | $17 |
| Amlodipine Besylate | 14 | $179 | $13 |
Money from drug and device companies
$66 in 2025
| 2025 | 2 | 3 | None | $66 |
| 2022 | 2 | 3 | None | $53 |
| 2021 | 1 | 1 | None | $209 |
| 2020 | 1 | 1 | None | $17 |
| 2019 | 1 | 1 | None | $17 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Access Pro Medical | Matriderm | $45 | 2 payments
|
| Aimmune Therapeutics | Vowst | $21 | 1 payment
|
See all 3 published payments
| Access Pro Medical | Meals · 2025-06-17 | Matriderm | $22 |
| Access Pro Medical | Meals · 2025-05-08 | Matriderm | $24 |
| Aimmune Therapeutics | Meals · 2025-04-02 | Vowst | $21 |
See earlier years (2022, 2021, 2020, 2019)
2022: $53
| Biohaven Pharmaceutical Holding Company | Nurtec Odt | $30 | 2 payments
|
| Harmony Biosciences | Wakix | $23 | 1 payment
|
2021: $209
| Stryker | Spy-Phi System | $209 | 1 payment
|
2020: $17
| Mylan Pharmaceuticals | Xulane | $17 | 1 payment
|
2019: $17
| Mylan Pharmaceuticals | Xulane | $17 | 1 payment
|
Professional record
- NPI
- 1639330806
- Licence
- CA C149397California C149397: Current · expires 2028-09-30
- Trained
- Tufts University School of Medicine, 2008
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Internal medicine (207R00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2008-06-20
- NPI last updated
- 2024-04-18
- NPI record certified
- 2024-04-18
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 211 Quarry Rd Ste 305, Palo Alto, CA, 94304 · 1701 High St Ste 102, Portsmouth, VA, 23704